share_log

Jin Medical International | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

中進醫療 | 6-K:外國發行人報告

美股sec公告 ·  01/11 13:00
牛牛AI助理已提取核心訊息
Jin Medical International Ltd. has announced an Extraordinary General Meeting (EGM) to be held on January 30, 2024, at 9.30 a.m. Beijing Time, with a record date of January 12, 2024. The primary agenda for the EGM is to seek shareholder approval for the subdivision of each issued and unissued ordinary share with a par value of US$0.001 into twenty ordinary shares with a par value of US$0.00005 each. This move, if approved, would increase the authorized share capital to US$50,000 divided into 1,000,000,000 shares. The Board unanimously recommends a vote in favor of the proposal. The subdivision is a strategic response to a letter from Nasdaq's Listing Qualifications Department, which indicated the company's non-compliance with the minimum public holder requirement. A...Show More
Jin Medical International Ltd. has announced an Extraordinary General Meeting (EGM) to be held on January 30, 2024, at 9.30 a.m. Beijing Time, with a record date of January 12, 2024. The primary agenda for the EGM is to seek shareholder approval for the subdivision of each issued and unissued ordinary share with a par value of US$0.001 into twenty ordinary shares with a par value of US$0.00005 each. This move, if approved, would increase the authorized share capital to US$50,000 divided into 1,000,000,000 shares. The Board unanimously recommends a vote in favor of the proposal. The subdivision is a strategic response to a letter from Nasdaq's Listing Qualifications Department, which indicated the company's non-compliance with the minimum public holder requirement. A subsequent delisting notification was received, but the delisting action has been stayed pending a final decision by the Nasdaq Hearings Panel, with a hearing scheduled for March 14, 2024. The proposed share subdivision aims to increase the number of shares outstanding, improve trading liquidity, and potentially increase the number of shareholders to meet Nasdaq's continued listing requirements.
金醫療國際有限公司宣佈特別股東大會(EGM)將於北京時間2024年1月30日上午9點30分舉行,創紀錄的日期爲2024年1月12日。股東特別大會的主要議程是尋求股東批准,將每股面值爲0.001美元的已發行和未發行普通股細分爲二十股普通股,每股面值爲0.00005美元。這一舉措如果獲得批准,將把法定股本增加到5萬美元,分成1,000,000股。董事會一致建議對該提案投贊成票。該細分是對納斯達克上市資格部門的一封信的戰略回應,該信表明該公司未遵守最低公衆持有人要求。隨後收到了除名通知,但除名行動已暫停,等待納斯達克聽證會小組做出最終決定,聽證會定於2024年3月14日舉行。擬議的股份分割旨在增加已發行股票的數量,改善交易流動性,並有可能增加股東數量,以滿足納斯達克的持續上市要求。
金醫療國際有限公司宣佈特別股東大會(EGM)將於北京時間2024年1月30日上午9點30分舉行,創紀錄的日期爲2024年1月12日。股東特別大會的主要議程是尋求股東批准,將每股面值爲0.001美元的已發行和未發行普通股細分爲二十股普通股,每股面值爲0.00005美元。這一舉措如果獲得批准,將把法定股本增加到5萬美元,分成1,000,000股。董事會一致建議對該提案投贊成票。該細分是對納斯達克上市資格部門的一封信的戰略回應,該信表明該公司未遵守最低公衆持有人要求。隨後收到了除名通知,但除名行動已暫停,等待納斯達克聽證會小組做出最終決定,聽證會定於2024年3月14日舉行。擬議的股份分割旨在增加已發行股票的數量,改善交易流動性,並有可能增加股東數量,以滿足納斯達克的持續上市要求。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。